Clinical Trial Update: Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial registry is evaluating maternal, infant, and lactation outcomes in patients using anifrolumab for systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus | Phase 4 | Status: RECRUITING